FY2024 EPS Estimates for VYGR Decreased by Leerink Partnrs

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Stock analysts at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for Voyager Therapeutics in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will post earnings of ($0.66) per share for the year, down from their prior forecast of ($0.44). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.20) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at ($0.45) EPS.

A number of other research firms have also recently commented on VYGR. Wedbush dropped their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, November 10th. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $5.64 on Friday. Voyager Therapeutics has a 52 week low of $5.59 and a 52 week high of $11.72. The stock has a market capitalization of $308.11 million, a P/E ratio of 7.94 and a beta of 0.89. The stock has a fifty day moving average of $6.62 and a 200-day moving average of $7.50.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the business earned ($0.59) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC grew its holdings in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares during the period. Vanguard Group Inc. grew its stake in shares of Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after buying an additional 702,030 shares during the period. Farallon Capital Management LLC grew its stake in shares of Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after buying an additional 1,000,000 shares during the period. Great Point Partners LLC bought a new stake in Voyager Therapeutics in the 2nd quarter valued at about $12,668,000. Finally, Geode Capital Management LLC raised its stake in Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after buying an additional 6,740 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.